This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2242v1 69/5/1776    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Suvà, M.-L. Articles by Stamenkovic, I. Search for Related Content PubMed PubMed Citation Articles by Suvà, M.-L. Articles by Stamenkovic, I.

Identification of Cancer Stem Cells in Ewing's Sarcoma

¹ Division of Experimental Pathology and Division of Clinical Pathology, Institute of Pathology and ² Department of Pediatric Surgery, University of Lausanne, Lausanne, Switzerland; Departments of ³ Orthopedics and ⁴ Neurosurgery, University of Geneva, Geneva, Switzerland; and ⁵ Department of Genetics, Biology, and Biochemistry, University of Turin, Turin, Italy

Requests for reprints: Ivan Stamenkovic, University of Lausanne, 25 Rue du Bugnon, Lausanne CH-1011, Switzerland. Phone: 41-21-314-7136; Fax: 41-21-314-7110; E-mail: Ivan.Stamenkovic{at}chuv.ch.

Key Words: Cancer stem cells • CD133 • Ewing's sarcoma

Cancer stem cells that display tumor-initiating properties have recently been identified in several distinct types of malignancies, holding promise for more effective therapeutic strategies. However, evidence of such cells in sarcomas, which include some of the most aggressive and therapy-resistant tumors, has not been shown to date. Here, we identify and characterize cancer stem cells in Ewing's sarcoma family tumors (ESFT), a highly aggressive pediatric malignancy believed to be of mesenchymal stem cell (MSC) origin. Using magnetic bead cell separation of primary ESFT, we have isolated a subpopulation of CD133+ tumor cells that display the capacity to initiate and sustain tumor growth through serial transplantation in nonobese diabetic/severe combined immunodeficiency mice, re-establishing at each in vivo passage the parental tumor phenotype and hierarchical cell organization. Consistent with the plasticity of MSCs, in vitro differentiation assays showed that the CD133+ cell population retained the ability to differentiate along adipogenic, osteogenic, and chondrogenic lineages. Quantitative real-time PCR analysis of genes implicated in stem cell maintenance revealed that CD133+ ESFT cells express significantly higher levels of OCT4 and NANOG than their CD133– counterparts. Taken together, our observations provide the first identification of ESFT cancer stem cells and demonstration of their MSC properties, a critical step towards a better biological understanding and rational therapeutic targeting of these tumors. [Cancer Res 2009;69(5):1776–81]